WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) recently completed its U.S. application for approval of QTORIN™ rapamycin to treat microcystic lymphatic malformations, putting the Wayne-based biotechnology company on a regulatory path that could support a commercial launch in the first half of 2027.
Palvella completed the rolling submission of its New Drug Application to the U.S. Food and Drug Administration for QTORIN 3.9% rapamycin anhydrous gel, according to the company. There are currently no FDA-approved therapies for the rare genetic disorder.
The FDA has 60 days to determine whether the application is sufficiently complete for review and whether to grant Priority Review. A Priority Review designation would set a six-month review goal.
QTORIN rapamycin previously received FDA Breakthrough Therapy, Fast Track and Orphan Drug designations.
The application is supported by Palvella’s Phase 3 SELVA trial, which met its primary endpoint, a prespecified key secondary endpoint and four additional secondary efficacy endpoints. All six efficacy endpoints achieved statistical significance with p-values below 0.001, according to the company.
Among trial participants age 6 and older who completed the efficacy evaluation period, 86% were rated “Much Improved” or “Very Much Improved” at week 24 using the Microcystic Lymphatic Malformation Investigator Global Assessment, the study’s primary endpoint.
Palvella reported no drug-related serious adverse events in SELVA. Systemic rapamycin concentrations remained below 2 nanograms per milliliter at all measured time points for all participants.
The NDA also incorporates Phase 2 results that supported the FDA’s Breakthrough Therapy designation, along with published literature and other evidence involving off-label use of rapamycin for microcystic lymphatic malformations.
Palvella filed under the FDA’s 505(b)(2) pathway, which permits the agency to rely partly on previous findings of safety and effectiveness and other existing data rather than requiring an application to depend exclusively on studies conducted by the applicant.
“Completing the submission of our NDA brings us one step closer to our goal of delivering the first FDA-approved therapy for patients living with microcystic LMs,” Chief Executive Officer Wes Kaupinen said.
Microcystic lymphatic malformations are a rare, chronic genetic disease involving abnormal lymphatic vessels. Palvella estimates that more than 30,000 pediatric and adult patients in the U.S. have the condition.
The company is preparing its commercial infrastructure ahead of a potential first-half 2027 launch if the treatment receives FDA approval. Palvella has assembled commercial leadership, deployed medical science liaisons across the U.S. and established a patient-services organization as part of those preparations.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.